Analyzing Gossamer Bio (NASDAQ:GOSS) and Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Profitability

This table compares Amylyx Pharmaceuticals and Gossamer Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amylyx Pharmaceuticals N/A -41.54% -38.91%
Gossamer Bio -159.49% N/A -112.10%

Insider & Institutional Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Amylyx Pharmaceuticals and Gossamer Bio”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amylyx Pharmaceuticals $87.37 million 39.17 -$144.74 million ($1.44) -18.49
Gossamer Bio $48.47 million 1.44 -$170.37 million ($46.56) -0.25

Amylyx Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amylyx Pharmaceuticals has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Amylyx Pharmaceuticals and Gossamer Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals 1 0 6 2 3.00
Gossamer Bio 2 3 5 0 2.30

Amylyx Pharmaceuticals presently has a consensus target price of $43.71, suggesting a potential upside of 64.22%. Gossamer Bio has a consensus target price of $246.40, suggesting a potential upside of 2,055.73%. Given Gossamer Bio’s higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Amylyx Pharmaceuticals.

Summary

Amylyx Pharmaceuticals beats Gossamer Bio on 11 of the 15 factors compared between the two stocks.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.